Sanofi - ADR (SNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNY POWR Grades
- Value is the dimension where SNY ranks best; there it ranks ahead of 91.28% of US stocks.
- The strongest trend for SNY is in Stability, which has been heading down over the past 179 days.
- SNY ranks lowest in Momentum; there it ranks in the 8th percentile.
SNY Stock Summary
- With a market capitalization of $129,944,581,874, Sanofi has a greater market value than 98.13% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Sanofi is reporting a growth rate of 151.38%; that's higher than 86.84% of US stocks.
- In terms of volatility of its share price, SNY is more volatile than only 2.24% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are GSK, DE, IBM, CAT, and AMGN.
- SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.
SNY Stock Price Chart Interactive Chart >
SNY Price/Volume Stats
| Current price | $54.40 | 52-week high | $58.10 |
| Prev. close | $53.06 | 52-week low | $46.92 |
| Day low | $53.78 | Volume | 1,938,600 |
| Day high | $54.57 | Avg. volume | 2,047,561 |
| 50-day MA | $53.03 | Dividend yield | 2.37% |
| 200-day MA | $51.05 | Market Cap | 137.48B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
Latest SNY News From Around the Web
Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Drugmakers Seek Emergency Authorization For New COVID VaccineWatch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID... |
Canada Approves First Plant-Based COVID-19 VaccineAs Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline Plc''s (NYSE: GSK ) COVID-19 vaccine finally heads to regulators, another shot using GSK''s pandemic adjuvant has won its first global approval . Mitsubishi Tanabe Pharma Corporation -backed Medicago''s recombinant COVID-19 vaccine, dubbed Covifenz, has snagged a green light in Canada in individuals 18 to 64 years of age. The vaccine uses a plant-based virus-like particles technology to mimic … Full story available on Benzinga.com |
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets GoalsGlaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds. |
France''s Sanofi to seek Covid vaccine approval after months of delaysFrench pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain''s GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals. |
Sanofi, GSK say vaccine shows 100% efficacy against hospitalization due to severe disease: Live COVID updatesSanofi and GSK seek approval for a vaccine they say shows 100% efficacy against hospitalization due to severe disease in human trials. COVID updates. |
SNY Price Returns
| 1-mo | -0.24% |
| 3-mo | 6.13% |
| 6-mo | 10.05% |
| 1-year | 3.11% |
| 3-year | 42.34% |
| 5-year | 31.28% |
| YTD | 11.21% |
| 2021 | 5.87% |
| 2020 | -0.83% |
| 2019 | 23.73% |
| 2018 | 4.20% |
| 2017 | 8.73% |
SNY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching SNY
Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...